当前位置： SCI文献检索 > CANCER GENE THERAPY期刊下所有文献 > Development of a novel adenovirus-alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction.

Development of a novel adenovirus-alphavirus hybrid vector with RNA replicon features for malignant hematopoietic cell transduction.

Abstract：

:To improve the expression levels of transgenes in malignant hematopoietic cells, we developed a novel adenoviral-alphavirus hybrid vector Ad5/F11p-SFV-GFP that contains a Semliki Forest Virus (SFV) replicon and chimeric fibers of Ad5 and Ad11p. Ad5/F11p-SFV-GFP infected >95% of K562, U937 or Jurkat cells and 23.65% of HL-60 cells, and led to moderate Enhanced Green Fluorescent Protein (EGFP) transgene expression intensity. The infection efficiency of Ad5/F11p-SFV-GFP in primary human leukemia cells ranged from 9.34-89.63% (median, 28.58%) at a multiplicity of infection (MOI) of 100, compared with only 3.37-44.54% (median, 10.42%) in cells infected by Ad5/F11p-GFP. Importantly, Ad5/F11p-SFV-GFP led to a significantly higher transgene expression level in primary leukemia cells, as indicated by the relative fluorescence intensity, compared to cells infected with Ad5/F11p-GFP. The increased expression of EGFP in Ad5/F11p-SFV-GFP-infected cells was associated with the accumulation of abundant subgenomic mRNA. Additionally, infection of K562, U937 or Jurkat cells by Ad5/F11p-SFV-GFP was significantly inhibited by blocking CD46 receptor; however, other factors may affect the gene-transfer efficiency of Ad5/F11p-SFV-GFP in primary leukemia cells. In conclusion, we successfully developed a novel adenoviral-alphavirus hybrid vector with RNA replicon features, which represents a promising vector for gene modifications during the production of cell-based vaccines for leukemia patients.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Yang Y,Xiao F,Lu Z,Li Z,Zuo H,Zhang Q,Li Q,Wang H,Wang LS

doi

10.1038/cgt.2013.37

subject

Has Abstract

pub_date

2013-08-01 00:00:00

pages

429-36

issue

8

eissn

0929-1903

issn

1476-5500

pii

cgt201337

journal_volume

20

pub_type

杂志文章

相关文献

CANCER GENE THERAPY文献大全
  • CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma.

    abstract：:Glioma is the most common tumor in the central nervous system that portends a poor prognosis. Key genes negatively related to survival may provide targets for therapy to improve the outcome of glioma. Here, we report a protein-coding gene CLEC5A, which is the top 1 gene by univariate Cox regression analysis of 524 pri...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0140-8

    authors： Tong L,Li J,Choi J,Pant A,Xia Y,Jackson C,Liu P,Yi L,Boussouf E,Lim M,Yang X

    更新日期：2020-09-01 00:00:00

  • Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.

    abstract：:The antitumor activity of a recombinant canarypox virus expressing wild type murine p53 (ALVAC-p53) was investigated in two murine syngeneic tumors harboring an endogenous p53 mutation (CMS4 and TS/A). Direct intratumor injections of ALVAC-p53 in CMS4 pre-established subcutaneous tumors induced total tumor regression ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700279

    authors： Odin L,Favrot M,Poujol D,Michot JP,Moingeon P,Tartaglia J,Puisieux I

    更新日期：2001-02-01 00:00:00

  • Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

    abstract：:MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (approximately 22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2008.8

    authors： Tong AW,Nemunaitis J

    更新日期：2008-06-01 00:00:00

  • Mdr1 promoter-driven tumor necrosis factor-alpha expression for a chemotherapy-controllable combined in vivo gene therapy and chemotherapy of tumors.

    abstract：:Cancer gene therapy approaches are often designed as single-agent treatments; however, greater therapeutic effect might be obtained if combined with an established conventional treatment regimen such as chemotherapy. In this context, conditional promoters are useful tools, because they may be induced by therapeutic mo...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700196

    authors： Walther W,Stein U,Fichtner I,Alexander M,Shoemaker RH,Schlag PM

    更新日期：2000-06-01 00:00:00

  • Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells.

    abstract：:Survivin is expressed in most cancers but is undetectable in differentiated adult cells, and plays an important role both in the suppression of apoptosis and mitotic spindle checkpoint; thus it has attracted great interest as a potential drug target. In this study, we investigated the antigene and antiproliferative ef...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700581

    authors： Shen C,Buck A,Polat B,Schmid-Kotsas A,Matuschek C,Gross HJ,Bachem M,Reske SN

    更新日期：2003-05-01 00:00:00

  • Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.

    abstract：:The gene transfer of tumor-specific chimeric immunoglobulin T-cell receptors (cIgTCRs) combining antibody-like specificity with the effector cell function could be an attractive tool in immunotherapy. In this study, we directed the human natural killer (NK) cell line YT to tumor cells by gene transfer of a cIgTCR with...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700453

    authors： Schirrmann T,Pecher G

    更新日期：2002-04-01 00:00:00

  • Targeting gene expression to tumor cells with loss of wild-type p53 function.

    abstract：:The tumor suppressor protein p53 is a transcription factor that can positively regulate the expression of critical target genes involved in negative control of cell growth or induction of apoptosis; p53 is also able to suppress the transcription of other genes by virtue of its ability to bind components of the basal t...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700091

    authors： Zhu J,Gao B,Zhao J,Balmain A

    更新日期：2000-01-01 00:00:00

  • Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.

    abstract：:Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers. Although the cure rate for sarcomas in general has significantly improved in the last 10 years, there continue to be subgroups that are difficult to treat. High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700798

    authors： Ganjavi H,Gee M,Narendran A,Freedman MH,Malkin D

    更新日期：2005-04-01 00:00:00

  • Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.

    abstract：:Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.4

    authors： García-Castro J,Alemany R,Cascalló M,Martínez-Quintanilla J,Arriero Mdel M,Lassaletta A,Madero L,Ramírez M

    更新日期：2010-07-01 00:00:00

  • Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.

    abstract：:In this study, we investigated the safety and efficacy in cancer patients of a single intra-tumor injection of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene (AdV/TK) followed by systemic administration of ganciclovir (GCV). In 18 patients with malignant tumors refractory to standard...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2009.19

    authors： Xu F,Li S,Li XL,Guo Y,Zou BY,Xu R,Liao H,Zhao HY,Zhang Y,Guan ZZ,Zhang L

    更新日期：2009-09-01 00:00:00

  • An HSVtk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice.

    abstract：:The "bystander effect," produced by ganciclovir-mediated killing of cells transduced with a herpes simplex virus thymidine kinase (HSVtk) gene, defines the cooperative killing of non-HSVtk-transduced cells. In vitro, a major contributor to this phenomenon is metabolic cooperation involving transfer of cytotoxic small ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Bi W,Kim YG,Feliciano ES,Pavelic L,Wilson KM,Pavelic ZP,Stambrook PJ

    更新日期：1997-07-01 00:00:00

  • E6AP gene suppression and characterization with in vitro selected hammerhead ribozymes.

    abstract：:E6AP was originally identified as the ubiquitin-protein ligase involved in human papillomavirus (HPV) E6-mediated p53 degradation and has since been shown to act as an E3 ubiquitin-protein ligase in the ubiquitination of several other protein substrates. To further define E6AP function at the molecular and cellular le...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700623

    authors： Kim Y,Cairns MJ,Marouga R,Sun LQ

    更新日期：2003-09-01 00:00:00

  • Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

    abstract：BACKGROUND:Interferon-gamma (IFN-gamma) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a regression of established tumors in animal models. The purpose of this trial was to determine the feasibility and safety of a direct intratumoral inject...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.cgt.7700019

    authors： Nemunaitis J,Fong T,Robbins JM,Edelman G,Edwards W,Paulson RS,Bruce J,Ognoskie N,Wynne D,Pike M,Kowal K,Merritt J,Ando D

    更新日期：1999-07-01 00:00:00

  • microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner.

    abstract：:Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death worldwide. Accumulating research has highlighted the ability of exosome-encapsulated microRNAs (miRNAs or miRs) as potential circulating biomarkers for lung cancer. The current study aimed to evaluate the clinical significance of seru...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-00216-1

    authors： Xu S,Zheng L,Kang L,Xu H,Gao L

    更新日期：2020-12-09 00:00:00

  • Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.

    abstract：:We present here the updated results after 9 years of the beginning of a trial on canine patients with malignant melanoma. This surgery adjuvant approach combined local suicide gene therapy with a subcutaneous vaccine composed by tumor cells extracts and xenogeneic cells producing human interleukin-2 and granulocyte-ma...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/cgt.2012.72

    authors： Finocchiaro LM,Glikin GC

    更新日期：2012-12-01 00:00:00

  • Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.

    abstract：:Breast cancer is the most common cause of cancer-related death worldwide, thus remaining a crucial health problem among women despite advances in conventional therapy. Therefore, new alternative strategies are needed for effective diagnosis and treatment. One approach is the use of oncolytic viruses for gene-directed ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.49

    authors： Seubert CM,Stritzker J,Hess M,Donat U,Sturm JB,Chen N,von Hof JM,Krewer B,Tietze LF,Gentschev I,Szalay AA

    更新日期：2011-01-01 00:00:00

  • RNA interference and potential therapeutic applications of short interfering RNAs.

    abstract：:RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/sj.cgt.7700857

    authors： Karagiannis TC,El-Osta A

    更新日期：2005-10-01 00:00:00

  • Transfection of NF-κB decoy oligodeoxynucleotide suppresses pulmonary metastasis by murine osteosarcoma.

    abstract：:Nuclear factor-kappa B (NF-κB) has a pivotal role in the progression and distant metastasis of cancers, including malignant bone tumors. To inhibit NF-κB activation, a new molecular therapy using synthetic double-stranded oligodeoxynucleotide (ODN) as a 'decoy' cis element against NF-κB has been developed. To determin...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.75

    authors： Nishimura A,Akeda K,Matsubara T,Kusuzaki K,Matsumine A,Masuda K,Gemba T,Uchida A,Sudo A

    更新日期：2011-04-01 00:00:00

  • Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect.

    abstract：:Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrat...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2008.20

    authors： Peled M,Shaish A,Greenberger S,Katav A,Hodish I,Ben-Shushan D,Barshack I,Mendel I,Frishman L,Tal R,Bangio L,Breitbart E,Harats D

    更新日期：2008-08-01 00:00:00

  • Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

    abstract：:The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte p...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.cgt.7700138

    authors： Yen N,Ioannides CG,Xu K,Swisher SG,Lawrence DD,Kemp BL,El-Naggar AK,Cristiano RJ,Fang B,Glisson BS,Hong WK,Khuri FR,Kurie JM,Lee JJ,Lee JS,Merritt JA,Mukhopadhyay T,Nesbitt JC,Nguyen D,Perez-Soler R,Pisters KM,P

    更新日期：2000-04-01 00:00:00

  • HJURP knockdown disrupts clonogenic capacity and increases radiation-induced cell death of glioblastoma cells.

    abstract：:The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centrome...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-019-0103-0

    authors： Serafim RB,Cardoso C,Di Cristofaro LFM,Pienna Soares C,Araújo Silva W Jr,Espreafico EM,Paçó-Larson ML,Price BD,Valente V

    更新日期：2020-05-01 00:00:00

  • Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.

    abstract：:The highly metastatic ESb tumor is totally resistant to murine interferon-alpha/beta (IFN-alpha/beta) therapy, regardless of the number of cells injected or the route of inoculation. In contrast, as we show herein, mouse IFN-alpha1-transduced ESb tumor cells were inhibited markedly when injected subcutaneously into im...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700051

    authors： Rozera C,Mecchia M,Gresser I,Bandu MT,Proietti E,Venditti M,Sestili P,Santini SM,Fais S,Belardelli F,Ferrantini M

    更新日期：1999-05-01 00:00:00

  • Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo.

    abstract：:Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700967

    authors： Chen G,Zhou J,Gao Q,Huang X,Li K,Zhuang L,Huang M,Xu G,Wang S,Lu Y,Ma D

    更新日期：2006-10-01 00:00:00

  • Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.

    abstract：:The majority of human neuroblastomas express low to undetectable levels of major histocompatibility complex (MHC) class I and II antigens (MHC-I and -II). We studied the effects of gamma interferon (gamma-IFN) transduction on expression of these antigens in six human neuroblastoma cell lines with and without genomic a...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Uçar K,Seeger RC,Challita PM,Watanabe CT,Yen TL,Morgan JP,Amado R,Chou E,McCallister T,Barber JR

    更新日期：1995-09-01 00:00:00

  • Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.

    abstract：:A phase I clinical trial using autologous, IL-7 gene-modified tumor cells in patients with disseminated melanoma has been recently completed. Although no major clinical responses were observed, increased antitumor cytotoxicity was measured in postvaccine peripheral blood lymphocytes in a subset of treated patients. To...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.cgt.7700435

    authors： Carsana M,Tragni G,Nicolini G,Bersani I,Parmiani G,Anichini A,Sun YS,Möller P,Schadendorf D,Sensi ML

    更新日期：2002-03-01 00:00:00

  • A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.

    abstract：:Thymidylate synthase (TS) catalyzes de novo production of thymidylate for DNA synthesis and cell proliferation. As such, TS has been a target of antitumor chemotherapy for many years. Our laboratory has identified several antisense oligodeoxynucleotides (ODNs) that downregulate TS mRNA and protein, inhibit cell prolif...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700566

    authors： Berg RW,Ferguson PJ,Vincent MD,Koropatnick DJ

    更新日期：2003-04-01 00:00:00

  • Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

    abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.22

    authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

    更新日期：2010-09-01 00:00:00

  • Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene.

    abstract：:The herpes simplex virus thymidine kinase gene (HSV-TK) in combination with ganciclovir (GCV), is currently being used in gene therapy-based clinical trials for cancer treatment. Its therapeutic effect is based on a "bystander effect" whereby HSV-TK gene-modified tumor cells are toxic to nearby unmodified tumor cells ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Ramesh R,Munshi A,Abboud CN,Marrogi AJ,Freeman SM

    更新日期：1996-11-01 00:00:00

  • Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model.

    abstract：:Adenovirus (Adv)-mediated herpes simplex virus thymidine kinase (adv/tk) gene therapy combined with ganciclovir (GCV) medication is a promising approach for the treatment of malignant glioma. However, optimal administration and the effect of possible adjuvant treatments have not been fully examined. In the present stu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700515

    authors： Tyynelä K,Sandmair AM,Turunen M,Vanninen R,Vainio P,Kauppinen R,Johansson R,Vapalahti M,Ylä-Herttuala S

    更新日期：2002-11-01 00:00:00

  • Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity.

    abstract：:The use of prodrug-activated ("suicide") gene therapy has been shown to be effective in inducing tumor regression when only a small proportion of tumor cells contains the suicide gene. These experiments were designed to test whether additional therapeutic benefit may be obtained by stimulating the immune response. Mur...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700259

    authors： Jones RK,Pope IM,Kinsella AR,Watson AJ,Christmas SE

    更新日期：2000-12-01 00:00:00